Coya Therapeutics, Inc.
COYAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | maintain | Buy | Sep 15, 2026 |
| Roth Capital | maintain | Buy | Aug 24, 2026 |
| Chardan Capital | maintain | Buy | Aug 12, 2026 |
| Chardan Capital | maintain | Buy | Jun 12, 2026 |
| D. Boral Capital | maintain | Buy | Apr 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 23, 2026 |
| D. Boral Capital | maintain | Buy | Mar 19, 2026 |
| Chardan Capital | maintain | Buy | Mar 16, 2026 |
| D. Boral Capital | maintain | Buy | Mar 16, 2026 |
| D. Boral Capital | maintain | Buy | Feb 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 2, 2026 |
| D. Boral Capital | maintain | Buy | Jan 21, 2026 |
| D. Boral Capital | maintain | Buy | Jan 8, 2026 |
| Chardan Capital | maintain | Buy | Jan 8, 2026 |
| D. Boral Capital | maintain | Buy | Jan 5, 2026 |
| D. Boral Capital | maintain | Buy | Dec 23, 2025 |
| D. Boral Capital | maintain | Buy | Dec 9, 2025 |
| Chardan Capital | maintain | Buy | Nov 14, 2025 |
| BTIG | maintain | Buy | Nov 13, 2025 |
| D. Boral Capital | maintain | Buy | Nov 12, 2025 |
| BTIG | maintain | Buy | Sep 30, 2025 |
| D. Boral Capital | maintain | Buy | Sep 29, 2025 |
| D. Boral Capital | maintain | Buy | Sep 22, 2025 |
| D. Boral Capital | maintain | Buy | Sep 17, 2025 |
| Chardan Capital | maintain | Buy | Sep 17, 2025 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.35| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.28 | $-0.35 | $221.9K | $130.0K |
| May 12, 2026 | $-0.32 | $-0.39 | $300.0K | $150.0K |
| Mar 16, 2026 | $-0.34 | $-0.27 | $4.0M | $2.2M |
| Nov 12, 2025 | $-0.10 | $0.02 | $3.6M | $1.9M |
| Aug 12, 2025 | $-0.36 | $-0.22 | $163.6K | $783.3K |
| May 13, 2025 | $-0.44 | $-0.44 | $257.9K | $2.6M |
| Mar 18, 2025 | $-0.18 | $-0.26 | $2.0K | $100.0K |
| Nov 6, 2024 | $-0.26 | $-0.41 | — | $1.9M |
News
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).Coya plans to initiate the OLE in response to requests from ALSTARS inves…
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced the company will be participating in a panel discussion at Chardan's 10th Annual Healthcare Conference taking place on October 20 in New York.Panel Details:Title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's &.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company's Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya's combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral scle.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Company's ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya's combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (AL.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, “The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease,” which highlights the expanding therapeutic applic…
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. “During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “E.